Additionally, the particulate contaminants could potentially act as an emboli and impede blood flow ...

1. Hospira Recalling Selected Lots of IV Reglan and Zofran
Additionally, the particulate contaminants could potentially act as an emboli and impede blood flow
causing tissue/organ damage, especially in vulnerable patients such as those undergoing surgery.
Anyone with an existing inventory should stop use and distribution, quarantine the product
immediately and call Stericycle at (877) 497-3125 during business hours to arrange for the return of
the product. The affected lots were distributed nationwide between June 2013 and September 2013
to wholesalers/distributors, hospitals and pharmacies.
The administration of an injectable with the presence of foreign particulates may potentially result in
local inflammation, thrombophlebitis and/or low-level allergic response. NDC 0409-4755-03, Lots 29-
484-DK and 29-510-DK (the lot numbers may be followed by a 01) are packaged in a 2 mL single-
dose flip-top vial, with an expiration date of May 1, 2015. We encourage
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/uc
m271924.htm LINKING to this content; view our linking policy here.
. There is potential for the glass particulates to dislodge into the solution, says the FDA.
Replacement product from other lots is available.
Dan O'Connor
© Copyright Herrin Publishing Partners LP.
Both products are packaged as 25 units per carton/100 units per case in glass flip-top vials.
REPRODUCTION OF THIS COPYRIGHTED CONTENT IS STRICTLY PROHIBITED. Reglan and
Zofran prevent or treat nausea after surgery.
The recall is due to a confirmed vial defect where strands of glass were identified as being affixed to
the inside of the vial walls. NDC 0409-3414-01, Lot 28-104-DK (the lot number may be followed by a
01), is packaged in a 2 mL single-dose flip-top zofran lawsuit payout vial, with an expiration date of
October 1, 2014.

2. Ondansetron.
Published: October 2, 2013
Hospira has initiated a voluntary nationwide recall of 1 lot of Metoclopramide Injection (Reglan),
USP, 10 mg/2 mL (5 mg/mL) and 2 lots of Ondansetron Injection (Zofran), USP, 4 mg/2 mL, (2
mg/mL), says the FDA. To date, Hospira has not received reports of any adverse events associated
with this issue for these lots.
Here's how to tell if you have any affected lots.
Metoclopramide